Pasithea TherapeuticsKTTA
13F holders, Q2 2024 (June 30)7holders +1
2new positions
1sold out
$5.05avg. 13F price*
At the end of Q2 2024, 7 institutions reported holding Pasithea Therapeutics Corp. (KTTA) in their 13F filings, up 1 from Q1 2024. 2 opened new positions and 1 sold out. The largest holders were ADAR1 Capital Management, LLC ($140K), Tower Research Capital LLC (TRC) ($9K) and Royal Bank of Canada ($1K).
- Company
- Pasithea Therapeutics Corp.
- CUSIP
- 70261F202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $286 |
| Exits | 1 | $44 |
All 13F filers, Q1 2024 → Q2 2024: 517 shares bought and 576 shares sold, net −59 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| ADAR1 Capital Management, LLC | 0.03% | No change | 27,696 | $140K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +34.4% | 1,807 | $9K |
| Royal Bank of Canada | 0.00% | No change | 250 | $1K |
| JPMorgan Chase & Co. | 0.00% | No change | 150 | $785 |
| FMR LLC | 0.00% | New | 49 | $256 |
| UBS Group AG | 0.00% | Reduce -93.8% | 38 | $192 |
| Bank of America Corp. | 0.00% | New | 6 | $30 |
"% of holder's portfolio" is KTTA's weight in each manager's 13F, not the share of Pasithea Therapeutics Corp. the manager owns.